This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dykstra: Cash Flow Is Ka-Ching King

Tough opening day for the defending World Series champ Phillies on Sunday: The Atlanta Braves cooled the Phillies' jets, beating them 4-1. And in Baltimore on Monday, the Yankees' brand new, high-paid talent -- in the harsh glare of the spotlight -- couldn't stave off an opening day loss to the Orioles, 10-5.

Everyone feels like they've got a lot to live up to. But now that opening-day jitters are behind them, everyone can relax and play some ball.

I don't get jitters when picking stocks for my deep-in-the-money options trading system. You can follow my system -- which has a win record of 99-1 -- through a subscription to my Nails on the Numbers newsletter. One of my key measures in evaluating a pick is its cash flow.

Operating cash flow is reported in big, round numbers that need some context to see how good they really are. So today, let's look at the operating cash flow ratio, which is a company's operating cash flow divided by its current liabilities. What this gives us is a measure of how well a stock's cash flow covers its current liabilities.

The higher the ratio, the better. But few companies can approach a ratio of 1.0. Rather, many have cash-flow ratios that are near zero. But let's look at some cash-flow winners. Pfizer (PFE - Get Report), which won for me in October, had operating cash flow of $5.97 billion in December. With current liabilities of $27 billion, the pharmaceuticals giant had an operating cash-flow-to-current liabilities ratio of 0.22 that quarter. That is up from a ratio of 0.17 for the same quarter of the prior year.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DO $24.26 0.00%
GD $140.52 0.00%
LMT $232.38 0.00%
MSFT $49.87 0.00%
OXY $76.65 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports